BACKGROUND: This study was performed to define the clinical relevance of early changes of capillary 3beta-hydroxybutyrate (3betaOHB), for detection of metabolic deterioration before occurrence of overt diabetic ketoacidosis following interruption of continuous subcutaneous insulin infusion (CSII). METHODS: An open clinical trial was performed with eight patients with type 1 diabetes on CSII therapy. After an overnight fast, at 8 a.m. (T0) CSII was interrupted for 4 h. At noon (T240) CSII was re-established, and at 4 p.m. (T480) the study was ended. Blood glucose (BG) and capillary and plasma 3betaOHB were measured at 30-min intervals, plasma insulin at 60-min intervals, and urinary ketones at 120-min intervals. RESULTS: After CSII interruption mean BG increased from 149.8+/-54.4 mg/dL at T0 to 224.8+/-56.2 mg/dL at T240 (P<0.05), and mean capillary 3betaOHB increased from 0.1+/-0.1 mmol/L at T0 to 0.9+/-0.6 mmol/L at T240 (P<0.001). The rate of increase of capillary 3betaOHB was faster and significantly more relevant than that of BG (P<0.05). The restoration of CSII produced a significant reduction of mean BG and capillary 3betaOHB (T480, 119.5+/-24 mg/dL and 0.2+/-0.2 mmol/L, respectively; P<0.05 for both vs. T240). The recovery of capillary 3betaOHB was significantly faster than that of BG (P=0.03). CONCLUSIONS: The dynamic evaluation of changes of capillary 3betaOHB levels can represent a useful support to home BG monitoring in the event of CSII interruption, providing faster information on early metabolic deterioration due to insulin deprivation and allowing preventative action for avoiding the evolution towards overt diabetic ketoacidosis. After reintroduction of insulin infusion the monitoring of the faster recovery of 3betaOHB relative to BG can provide useful information for the prevention of late hypoglycemia due to insulin overinfusion.
BACKGROUND: This study was performed to define the clinical relevance of early changes of capillary 3beta-hydroxybutyrate (3betaOHB), for detection of metabolic deterioration before occurrence of overt diabetic ketoacidosis following interruption of continuous subcutaneous insulin infusion (CSII). METHODS: An open clinical trial was performed with eight patients with type 1 diabetes on CSII therapy. After an overnight fast, at 8 a.m. (T0) CSII was interrupted for 4 h. At noon (T240) CSII was re-established, and at 4 p.m. (T480) the study was ended. Blood glucose (BG) and capillary and plasma 3betaOHB were measured at 30-min intervals, plasma insulin at 60-min intervals, and urinary ketones at 120-min intervals. RESULTS: After CSII interruption mean BG increased from 149.8+/-54.4 mg/dL at T0 to 224.8+/-56.2 mg/dL at T240 (P<0.05), and mean capillary 3betaOHB increased from 0.1+/-0.1 mmol/L at T0 to 0.9+/-0.6 mmol/L at T240 (P<0.001). The rate of increase of capillary 3betaOHB was faster and significantly more relevant than that of BG (P<0.05). The restoration of CSII produced a significant reduction of mean BG and capillary 3betaOHB (T480, 119.5+/-24 mg/dL and 0.2+/-0.2 mmol/L, respectively; P<0.05 for both vs. T240). The recovery of capillary 3betaOHB was significantly faster than that of BG (P=0.03). CONCLUSIONS: The dynamic evaluation of changes of capillary 3betaOHB levels can represent a useful support to home BG monitoring in the event of CSII interruption, providing faster information on early metabolic deterioration due to insulin deprivation and allowing preventative action for avoiding the evolution towards overt diabetic ketoacidosis. After reintroduction of insulin infusion the monitoring of the faster recovery of 3betaOHB relative to BG can provide useful information for the prevention of late hypoglycemia due to insulin overinfusion.
Authors: David C Klonoff; Charles L Zimliki; Lcdr Alan Stevens; Patricia Beaston; Arleen Pinkos; Sally Y Choe; Guillermo Arreaza-Rubín; William Heetderks Journal: J Diabetes Sci Technol Date: 2011-05-01
Authors: R Paul Wadwa; H Peter Chase; Dan Raghinaru; Bruce A Buckingham; Irene Hramiak; David M Maahs; Laurel Messer; Trang Ly; Tandy Aye; Paula Clinton; Craig Kollman; Roy W Beck; John Lum Journal: Pediatr Diabetes Date: 2016-07-12 Impact factor: 4.866
Authors: Bruce A Buckingham; Fraser Cameron; Peter Calhoun; David M Maahs; Darrell M Wilson; H Peter Chase; B Wayne Bequette; John Lum; Judy Sibayan; Roy W Beck; Craig Kollman Journal: Diabetes Technol Ther Date: 2013-07-24 Impact factor: 6.118
Authors: Eyal Dassau; Fraser Cameron; Hyunjin Lee; B Wayne Bequette; Howard Zisser; Lois Jovanovic; H Peter Chase; Darrell M Wilson; Bruce A Buckingham; Francis J Doyle Journal: Diabetes Care Date: 2010-06 Impact factor: 17.152
Authors: Bruce Buckingham; H Peter Chase; Eyal Dassau; Erin Cobry; Paula Clinton; Victoria Gage; Kimberly Caswell; John Wilkinson; Fraser Cameron; Hyunjin Lee; B Wayne Bequette; Francis J Doyle Journal: Diabetes Care Date: 2010-03-03 Impact factor: 19.112
Authors: Kevin T Nguyen; Nicole Y Xu; Jennifer Y Zhang; Trisha Shang; Ananda Basu; Richard M Bergenstal; Kristin Castorino; Kong Y Chen; David Kerr; Suneil K Koliwad; Lori M Laffel; Nestoras Mathioudakis; L Kurt Midyett; Joshua D Miller; James H Nichols; Francisco J Pasquel; Priya Prahalad; Mark R Prausnitz; Jane Jeffrie Seley; Jennifer L Sherr; Elias K Spanakis; Guillermo E Umpierrez; Amisha Wallia; David C Klonoff Journal: J Diabetes Sci Technol Date: 2021-10-04
Authors: Roy W Beck; Dan Raghinaru; R Paul Wadwa; H Peter Chase; David M Maahs; Bruce A Buckingham Journal: Diabetes Care Date: 2014 Impact factor: 19.112
Authors: David M Maahs; Peter Calhoun; Bruce A Buckingham; H Peter Chase; Irene Hramiak; John Lum; Fraser Cameron; B Wayne Bequette; Tandy Aye; Terri Paul; Robert Slover; R Paul Wadwa; Darrell M Wilson; Craig Kollman; Roy W Beck Journal: Diabetes Care Date: 2014-05-07 Impact factor: 19.112